Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

No longer available 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Other hematologic neoplasm 2Other solid neoplasm 1

Conditions

Lung Neoplasms 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Powders × Thoracic × Clear all
NCT03756311 2026-01-23

Expanded Access to NanoPac

NanOlogy, LLC

No longer available
GenitourinaryThoracic

Lung Neoplasms, Prostatic Neoplasms

NCT04314895 2025-05-23

Trial of NanoPac Intratumoral Injection in Lung Cancer

NanOlogy, LLC

Phase 2 Completed
18 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡